Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
400 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.32 - $70.76
Previous Close$62.1
Volume1.57M
Average Volume (3M)1.64M
Market Cap
$7.11B
Enterprise Value$6.67B
Total Cash (Recent Filing)$551.80M
Total Debt (Recent Filing)$112.71M
Price to Earnings (P/E)-10.1
Beta0.82
Next Earnings
May 03, 2023EPS Estimate
-$1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding110,575,547
10 Day Avg. Volume1,015,643
30 Day Avg. Volume1,635,969
Standard Deviation0.17
R-Squared0.14
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)19.96
Price to Sales (P/S)116.30
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-16.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue88.43
Enterprise Value/Gross Profit95.57
Enterprise Value/Ebitda-10.80
Forecast
1Y Price Target
$78.73Price Target Upside28.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Apellis Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $33.32 and its highest was $70.75 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 03, 2023 which is in 41 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 21, 2023. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.528 by $0.028.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$1.47.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 114,465,300 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.528. Following the earnings report the stock price went up 12.513%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Farallon Capital Management, L.L.C.. It holds Apellis Pharmaceuticals Inc’s shares valued at 23M.
---
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.73 (28.62% Upside)
$78.73 (28.62% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $401.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.21%
12-Months-Change
Fundamentals
Return on Equity
-353.93%
Trailing 12-Months
Asset Growth
-13.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
---